Cargando…
Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse, mainly due to low levels of insight into the illness and nonadherence to their oral medication. Therefore, although the formal d...
Autores principales: | Přikryl, Radovan, Přikrylová Kučerová, Hana, Vrzalová, Michaela, Češková, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420571/ https://www.ncbi.nlm.nih.gov/pubmed/22966444 http://dx.doi.org/10.1155/2012/764769 |
Ejemplares similares
-
One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters)
por: Češková, Eva, et al.
Publicado: (2007) -
Psychopathology and treatment responsiveness of patients with first-episode schizophrenia
por: Češková, Eva, et al.
Publicado: (2005) -
Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012) -
Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013) -
Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)